openPR Logo
Press release

CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to Increasing Number of Patients Undergoing Chemotherapy

08-14-2018 03:40 PM CET | Health & Medicine

Press release from: Transparency Market Research

CINV Existing and Pipeline Drugs Market: Rising Demand for CINV

CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the latter occurs within 24 hours of a patient receiving chemotherapy.

Read Report Overview @ https://www.transparencymarketresearch.com/cinv-market.html

Based on the major drugs available on the market currently, the report segments the CINV existing drugs market as follows: Akynzeo (netupitant-palonosetron FDC), Aloxi (palonosetron), Zofran Generic (ondansetron), Emend (aprepitant), and Kytril Generic (granisetron). Drugs in the pipeline that are studied in the report include: Rolapitant and SUSTOL (granisetron injection extended release).

It is expected that the incidence rate of cancer will soar 17.1 million by 2020. With a growing prevalence rate of cancer across the world, more and more patients are expected to undergo chemotherapy. This alone will be a high-impact driver for the global CINV drugs market. Studies show that nearly 30% of all people suffering from cancer are advised to undergo chemotherapy. Of these, about 70% to 80% patients suffer from CINV.

In the light of these factors, the CINV existing and pipeline drugs market will receive a boost with the expected launch of new drugs such as SUSTOL (APF-530) and rolapitant. The efficacy of pipeline drugs that are at the clinical study stage has been reported to be higher than that of the current CINV treatment drugs on the market. This will likely lead to physicians prescribing newer drugs more as opposed to existing drugs.

Request for the Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776

The growth of the CINV drugs market is expected to be hampered to some degree by the patents of two leading drugs – Aloxi and Emend – lapsing. This will cause a dip in the revenue of CINV drugs over the forecast period of the report, which ranges from 2014 to 2020.

Studying the market from the regional perspective, the report states that North America was the largest CINV drugs market in 2013 and will remain in this position until 2020. The CINV drugs market in North America will receive a massive boost from rolapitant and SUSTOL. Europe followed North America in terms of CINV drugs revenue in 2013. The alarming increase in cancer cases reported from Asia Pacific and Rest of the World will enable the CINV drugs market to grow vigorously in these markets.

Companies that have secured a competitive edge in the global CINV drugs market are: Helsinn Holding S.A., GlaxoSmithKline plc, Merck & Co., Inc. Heron Therapeutics, Inc., and Tesaro, Inc.

Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=776

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to Increasing Number of Patients Undergoing Chemotherapy here

News-ID: 1180186 • Views: 265

More Releases from Transparency Market Research

Hemangioma Treatment Market to Experience Significant Growth During the Forecast …
Hemangioma Treatment Market: Introduction Hemangioma is a red color birthmark, usually appearing in the first and the second week of birth. Hemangioma is a benign or non-cancerous tumor, made of blood vessels and usually looks like rubbery bump on the skin. It occurs on the face, chest, scalp, and back. Various kinds of hemangioma appear in muscles, bone, or internal organs of the body. The primary site of occurrence is usually
Antihormonal Cancer Therapies Market Strategic Analysis to Understand the Compet …
Antihormonal Cancer Therapies Market: Introduction Hormones are chemicals that are naturally produced by the organs and regulate just about every cell in the body. Hormone therapy is also known as endocrine therapy. Insulin, thyroid hormone, epinephrine, cortisol, testosterone, and estrogen are some examples of hormones. Read Report Overview - https://www.transparencymarketresearch.com/antihormonal-cancer-therapies-market.html Key Drivers and Opportunities of Global Antihormonal Cancer Therapies Market Increase in incidence and prevalence of cancer such as breast cancer and prostate cancer
Single-cell Omics Market is Predicted to Experience Noticeable Growth by 2027
Global Single-cell Omics Market: Introduction Single cell genome-wide approaches provide a valuable opportunity to measure different molecules, such as DNA, RNA, protein, and chromatin with ultimate resolution. Utilizing these different single cell omics profiling strategies as building blocks, we can construct a multi-omics profile for the same cell. Development of high-throughput next-generation sequencing technology has enabled multiomics analysis at single-cell resolution. Read Report Overview - https://www.transparencymarketresearch.com/single-cell-omics-market.html Single-cell multiomics would also enhance our understanding
Arachnoiditis Treatment Market is Projected to Experience Promising Growth Oppor …
Arachnoiditis Treatment Market: Introduction Arachnoid is a thin and transparent membrane, also known as meninges, which protects the nerves of the spinal cord. Inflammation of the arachnoid results in a pain disorder, which leads to arachnoiditis. The inflammation occurs due to irritation from spine injury, chemicals, infections, compression in the spinal nerves, or post spine surgical complications. Read Report Overview - https://www.transparencymarketresearch.com/arachnoiditis-treatment-market.html The inflammation results into scar tissue and adhesions, which cause nerves

All 5 Releases


More Releases for CINV

CINV Existing and Pipeline Drugs Market is Expected to Surpass US$1.88 bn by 202 …
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Excellent Growth Scop …
A new research study from HTF MI with title Global Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs Market Size, Status and Forecast 2025 provides an in-depth assessment of the Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. The research study provides forecasts for Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs investments till 2022. Access
CINV Existing and Pipeline Drugs Market will Surpass US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
CINV Existing and Pipeline Drugs Market Projected to Reach US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow $2, 659 Million By 2 …
Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects, the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer. For More Info, Get Sample: http://bit.ly/2zVmL28 The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015 and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1%
Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 …
Chemotherapy-induced Nausea and Vomiting (CINV) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022. Access Full Summary At: https://www.alliedmarketresearch.com/cinv-market Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with